New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more. Related Content:

• A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026